8-Bromo-cAMP, sodium salt (Synonyms: 8-Br-cAMP, 8-Bromoadenosine 3',5'-cyclic monophosphate, 8-bromo-cAMP) |
| Catalog No.GC16929 |
Análogo de cAMP permeable a la célula que activa PKA.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 76939-46-3
Sample solution is provided at 25 µL, 10mM.
8-Bromo-cAMP (8-Bromo-cAMP, sodium salt) is a cell-permeable cAMP analogue that acts as a CAMP-dependent protein kinase activator (PKA activator). It has the ability to inhibit the growth of tumor cells and facilitate tumor differentiation [1-2].
8-Bromo-cAMP (20μM;24 h/48h) induced differentiation and apoptosis of human esophageal carcinoma cells Eca-109 [3]. 8-Bromo-cAMP (0.1/0.5 mM;10days) enhances the efficiency of inducing pluripotency in human fibroblast cells[4]. 8-Bromo-cAMP (250 μM) inhibits glucose transport activity in mouse placental cells in culture [5]. 8-Bromo-cAMP(0-1mM) induces a proliferative response in an IL-3 dependent leukemic cell line[6].
8-Bromo-cAMP (60 mg/kg/ day; 7 days; i.p) significantly inhibited the growth of CT26 tumor in mice[7]. 8-Bromo-cAMP enhances both humoral and cell-mediated immune responses induced by an HIV-1 DNA vaccine in mice[8].
References:
[1]. Chen TC, Hinton DR, et,al. Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab Invest. 1998 Feb;78(2):165-74. PMID: 9484714.
[2]. Li H, Chen HC, et,al.Identification of a rapidly dephosphorylating 95-kDa protein as elongation factor 2 during 8-Br-cAMP treatment of N1E115 neuroblastoma cells. Biochem Biophys Res Commun. 1995 Dec 5;217(1):131-7. doi: 10.1006/bbrc.1995.2754. PMID: 8526900.
[3]. Wang HM, Zheng NG, et,al. Dual effects of 8-Br-cAMP on differentiation and apoptosis of human esophageal cancer cell line Eca-109. World J Gastroenterol. 2005 Nov 7;11(41):6538-42. doi: 10.3748/wjg.v11.i41.6538. PMID: 16425431; PMCID: PMC4355801.
[4]. Wang Y, Adjaye J. A cyclic AMP analog, 8-Br-cAMP, enhances the induction of pluripotency in human fibroblast cells. Stem Cell Rev Rep. 2011 Jun;7(2):331-41. doi: 10.1007/s12015-010-9209-3. PMID: 21120637.
[5]. Sakata M, Yamaguchi M, et,al. 8-Bromo-cAMP inhibits glucose transport activity in mouse placental cells in culture. J Endocrinol. 1996 Aug;150(2):319-27. doi: 10.1677/joe.0.1500319. PMID: 8869598.
[6]. Barge RM, Falkenburg JH, et,al. 8-Bromo-cAMP induces a proliferative response in an IL-3 dependent leukemic cell line and activates Erk 1,2 via a Shc-independent pathway. Biochim Biophys Acta. 1997 Feb 4;1355(2):141-6. doi: 10.1016/s0167-4889(96)00130-9. PMID: 9042334.
[7]. Wang S, Zhang Z, et,al. Angiogenesis and vasculogenic mimicry are inhibited by 8-Br-cAMP through activation of the cAMP/PKA pathway in colorectal cancer. Onco Targets Ther. 2018 Jul 2;11:3765-3774. doi: 10.2147/OTT.S164982. PMID: 29997437; PMCID: PMC6033084.
[8]. Arai H, Xin KQ, et,al. 8 Br-cAMP enhances both humoral and cell-mediated immune responses induced by an HIV-1 DNA vaccine. Gene Ther. 2000 Apr;7(8):694-702. doi: 10.1038/sj.gt.3301145. PMID: 10800093.
|
Cell experiment [1]: |
|
|
Cell lines |
Eca-109 cells (human esophageal carcinoma cells) |
|
Preparation method |
Cells were cultured with 8-Bromo-cAMP for 24 h and 48h. |
|
Reaction Conditions |
20μmol/L;24 h/48h |
|
Applications |
8-Bromo-cAMP treatment induced differentiation and apoptosis in Eca-109 cell. |
|
Animal experiment [2]: |
|
|
Animal models |
BALB/c mice |
|
Preparation method |
Mice underwent implantation of CT26 carcinoma tissue in their cecum. The experimental group received intraperitoneal injections of 8-Bromo-cAMP, while the control group was injected with normal saline. |
|
Dosage form |
60 mg/kg/ day; 7 days; i.p |
|
Applications |
8-Bromo-cAMP significantly inhibited the growth of CT26 tumor in mice. |
|
References: [1]. Wang HM, Zheng NG, et,al. Dual effects of 8-Br-cAMP on differentiation and apoptosis of human esophageal cancer cell line Eca-109. World J Gastroenterol. 2005 Nov 7;11(41):6538-42. doi: 10.3748/wjg.v11.i41.6538. PMID: 16425431; PMCID: PMC4355801. [2]. Wang S, Zhang Z, et,al. Angiogenesis and vasculogenic mimicry are inhibited by 8-Br-cAMP through activation of the cAMP/PKA pathway in colorectal cancer. Onco Targets Ther. 2018 Jul 2;11:3765-3774. doi: 10.2147/OTT.S164982. PMID: 29997437; PMCID: PMC6033084. |
|
| Cas No. | 76939-46-3 | SDF | |
| Sinónimos | 8-Br-cAMP, 8-Bromoadenosine 3',5'-cyclic monophosphate, 8-bromo-cAMP | ||
| Chemical Name | sodium (4aR,6R,7R,7aS)-6-(6-amino-8-bromo-9H-purin-9-yl)-7-hydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate 2-oxide | ||
| Canonical SMILES | NC1=C(N=C(Br)N2[C@@H]3O[C@H](COP(O4)([O-])=O)[C@@H]4[C@H]3O)C2=NC=N1.[Na+] | ||
| Formula | C10H10BrN5NaO6P | M.Wt | 430.09 |
| Solubility | ≥ 43mg/mL in Water;DMSO : 250 mg/mL (581.29 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3251 mL | 11.6255 mL | 23.2509 mL |
| 5 mM | 0.465 mL | 2.3251 mL | 4.6502 mL |
| 10 mM | 0.2325 mL | 1.1625 mL | 2.3251 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 17 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *